Drug Type Enzyme |
Synonyms- |
Target |
Action modulators |
Mechanism ALP modulators(Alkaline phosphatases modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Organ Failure | Phase 2 | Belgium | 01 Sep 2004 | |
Multiple Organ Failure | Phase 2 | Netherlands | 01 Sep 2004 | |
Shock, Septic | Phase 2 | Belgium | 01 Sep 2004 | |
Shock, Septic | Phase 2 | Netherlands | 01 Sep 2004 |
Phase 2 | Oxygen radical damage adenosine | creatinine | cystatin-C | 11 | gpxsbiqkmp(rewmdpbbil) = There were no adverse events observed in the bRESCAP group. qynxivwmwe (fefivmmkqm ) | Negative | 03 May 2022 | ||
Placebo | |||||||
Phase 2 | Acute kidney injury due to sepsis renal KIM-1 | 36 | Alkaline Phosphatase | rirparimlq(rcjpqadjyh) = nlrdzjyknp extkvmklsc (mqzzukupkn ) | Positive | 16 Nov 2010 | |
Alkaline Phosphatase (Placebo) | rirparimlq(rcjpqadjyh) = couinjrmqq extkvmklsc (mqzzukupkn ) |